56.43
Schlusskurs vom Vortag:
$57.96
Offen:
$57.62
24-Stunden-Volumen:
2.52M
Relative Volume:
0.71
Marktkapitalisierung:
$25.01B
Einnahmen:
$2.44B
Nettoeinkommen (Verlust:
$1.36B
KGV:
29.56
EPS:
1.9093
Netto-Cashflow:
$574.14M
1W Leistung:
-2.32%
1M Leistung:
+3.50%
6M Leistung:
+40.48%
1J Leistung:
+56.23%
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
56.43 | 25.69B | 2.44B | 1.36B | 574.14M | 1.9093 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again - Yahoo Finance Singapore
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice - Yahoo! Finance Canada
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Russell 1000 Defensive Inclusion Might Change The Case For Investing In Royalty Pharma (RPRX) - simplywall.st
How (RPRX) Movements Inform Risk Allocation Models - Stock Traders Daily
RPRX or ACAD: Which Is the Better Value Stock Right Now? - Yahoo Finance
Royalty Pharma Q1 2026 earnings preview - MSN
Y Intercept Hong Kong Ltd Grows Stake in Royalty Pharma PLC $RPRX - MarketBeat
Swedbank AB Sells 355,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma stock hits all-time high at 58.02 USD - Investing.com
Royalty Pharma stock hits all-time high at 58.02 USD By Investing.com - Investing.com Nigeria
Royalty Pharma plc (RPRX) Stock Analysis: Navigating the Biotech Sector with Robust Revenue Growth - DirectorsTalk Interviews
Royalty Pharma PLC $RPRX Shares Sold by Inspire Investing LLC - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Has $439,000 Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Moran Wealth Management LLC Boosts Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ETFs Investing in Royalty Pharma Plc Class A Stocks - TradingView
USS Investment Management Ltd Boosts Position in Royalty Pharma PLC $RPRX - MarketBeat
Pictet Asset Management Holding SA Increases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $5,652,000.00 in Stock - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades - Stock Titan
Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M - Stock Titan
Form 144 Royalty Pharma PLC For: 1 July By Investing.com - Investing.com South Africa
[144] Royalty Pharma plc SEC Filing - Stock Titan
Royalty Pharma (RPRX) Shares Rally Following Earnings Report That Beat EstimatesTech Earnings Analysis - dars.gov.et
Form 4 Royalty Pharma Plc For: 30 June By Investing.com - Investing.com South Africa
Royalty Pharma (RPRX) director gets equity grant in lieu of cash - Stock Titan
Hsbc Holdings PLC Cuts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Joins Key Russell Indices, Is The Stock Fully Priced? - Sahm
Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month HighTime to Buy? - MarketBeat
Royalty Pharma stock hits all-time high at 56.57 USD By Investing.com - Investing.com Nigeria
Royalty Pharma stock hits all-time high at 56.57 USD - Investing.com
Royalty Pharma, plc (RPRX) Rallied on Earnings Beat - Insider Monkey
Royalty Pharma (RPRX) Stock Analysis: Evaluating Its 5.37% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Rockefeller Capital Management L.P. Purchases 81,747 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Does Royalty Pharma’s (RPRX) Index Upgrade Signal Deeper Defensive Strength In Its Business Model? - simplywall.st
Royalty Pharma plc(NasdaqGS: RPRX) added to Russell 1000 Defensive Index - marketscreener.com
Enterprise value to revenue forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Trading Systems Reacting to (RPRX) Volatility - Stock Traders Daily
Royalty Pharma PLC $RPRX Shares Sold by Goodman Advisory Group LLC - MarketBeat
Enterprise value to EBITDA forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to EBIT forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Price to earnings forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to EBITDA forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to book forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Price to sales forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to revenue forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to sales forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Royalty Pharma Plc-Aktie (RPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.52 |
100,000 |
5,651,813 |
459,399 |
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.46 |
30,000 |
1,693,658 |
40,000 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):